About Us

We are a clinical-stage biopharmaceutical company with a Phase 3-ready program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders. We are developing these disease modifying treatments by leveraging our expertise in inhibiting protein misfolding and aggregation.

alzheon - Medicines for Alzheimer's Disease

Our Experienced Team

We are a passionate and highly experienced team of neuroscientists, pharmacologists, medicinal chemists, clinicians, drug developers and business leaders with a deep understanding of neurological and psychiatric disorders and a track record of successfully developing products to treat these diseases. We believe our team positions us to become a leading company developing disease modifying therapies for the treatment of neurodegenerative disorders.

Meet Our Team

ALZ-801 for Alzheimer’s

ALZ-801 is an oral small molecule inhibitor of beta amyloid misfolding and the consequent formation of small neurotoxic aggregates, or oligomers. In October 2017, the FDA designated ALZ-801 as a Fast Track development program for the investigation of Alzheimer’s disease and we intend to commence a Phase 3 trial for ALZ-801 in APOE4/4 homozygous patients with early to mild Alzheimer’s in 2019.

Discover ALZ-801

Other Programs

We have an extensive proprietary library of compounds designed to inhibit the misfolding of amyloid and other proteins associated with neurodegenerative diseases. We are investigating the next generation of protein misfolding inhibitors and intend to progress one or more of these compounds.

Explore Our Pipeline